In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight l ...
But almost as quickly as they arrived on the scene, Russia’s oligarchs soon became political targets themselves. In the first decade of this century, with the tumult of the prior decade receding, ...
Follow the Artemis mission to bring humanity back to the Moon for the first time since Apollo. A half-century after Apollo, the Artemis missions aim to bring astronauts back to the Moon and establish ...
No. 10 / 2026Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results